Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention

Heart Catheterization Clinical Trial

Official title:
The Safety and Pharmacodynamics of Two Doses of Dabigatran Etexilate in Patients Undergoing Cardiac Catheterization

Status Completed

Clinical Trial Summary

To assess whether two doses of dabigatran etexilate (110 mg twice daily (b.i.d) and 150 mg twice daily (b.i.d)) as compared to unfractionated heparin (UFH), both in addition to a standard dual antiplatelet regimen, provide sufficient anticoagulation in the setting of elective percutaneous coronary intervention (PCI).

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Heart Catheterization

Clinical Trial Details

NCT number	NCT00818753
Study type	Interventional
Source	Boehringer Ingelheim
Contact
Status	Completed
Phase	Phase 2
Start date	January 2009

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00968032` - Procedural Success and Safety of the Nit-Occlud® Patent Foramen Ovale (PFO) Closure Device and Its Application System	N/A
	Completed	`NCT03142126` - Accelerated Ambulation After Vascular Access Closure Device	N/A